BindingDB logo
myBDB logout

Patent code US10208081

Compile Data Set for Download or QSAR
Found 137 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Bile acid receptor


(Homo sapiens (Human))
BDBM21675
PNG
((4R)-4-[(1S,2S,5R,7S,8R,9R,10S,11S,14R,15R)-8-ethy...)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
Purchase

KEGG
MMDB
PC cid
PC sid
PDB
UniChem

Similars

MMDB
PDB
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
3D
3D Structure (crystal)
Bile acid receptor


(Homo sapiens (Human))
BDBM350709
PNG
(US10208081, Example 17)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(C)c(C)c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C34H54N2O5S/c1-7-25-29-19-23(37)12-15-34(29,6)28-13-16-33(5)26(10-11-27(33)30(28)31(25)38)21(3)14-17-35-32(39)36-42(40,41)24-9-8-20(2)22(4)18-24/h8-9,18,21,23,25-31,37-38H,7,10-17,19H2,1-6H3,(H2,35,36,39)/t21-,23-,25-,26-,27+,28+,29+,30+,31-,33-,34-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350716
PNG
(US10208081, Example 24)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cccc(Cl)c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H49ClN2O4S/c1-5-21-17-25-27-10-9-26(31(27,3)15-12-28(25)32(4)14-11-23(36)19-29(21)32)20(2)13-16-34-30(37)35-40(38,39)24-8-6-7-22(33)18-24/h6-8,18,20-21,23,25-29,36H,5,9-17,19H2,1-4H3,(H2,34,35,37)/t20-,21+,23-,25+,26-,27+,28+,29+,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350719
PNG
(US10208081, Example 27)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)C4CCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C31H54N2O4S/c1-5-21-18-24-26-11-10-25(20(2)14-17-32-29(35)33-38(36,37)23-8-6-7-9-23)30(26,3)16-13-27(24)31(4)15-12-22(34)19-28(21)31/h20-28,34H,5-19H2,1-4H3,(H2,32,33,35)/t20-,21+,22-,24+,25-,26+,27+,28+,30-,31-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350722
PNG
(US10208081, Example 30)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)C4CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C28H48N2O4S/c1-5-18-14-21-23-9-8-22(17(2)16-29-26(32)30-35(33,34)20-6-7-20)27(23,3)13-11-24(21)28(4)12-10-19(31)15-25(18)28/h17-25,31H,5-16H2,1-4H3,(H2,29,30,32)/t17-,18+,19-,21+,22-,23+,24+,25+,27-,28-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350723
PNG
(US10208081, Example 31)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)c4ccccc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C31H48N2O4S/c1-5-21-17-24-26-12-11-25(20(2)19-32-29(35)33-38(36,37)23-9-7-6-8-10-23)30(26,3)16-14-27(24)31(4)15-13-22(34)18-28(21)31/h6-10,20-22,24-28,34H,5,11-19H2,1-4H3,(H2,32,33,35)/t20-,21+,22-,24+,25-,26+,27+,28+,30-,31-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350724
PNG
(US10208081, Example 32)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)c4ccc5ccccc5c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C35H50N2O4S/c1-5-23-19-28-30-13-12-29(34(30,3)17-15-31(28)35(4)16-14-26(38)20-32(23)35)22(2)21-36-33(39)37-42(40,41)27-11-10-24-8-6-7-9-25(24)18-27/h6-11,18,22-23,26,28-32,38H,5,12-17,19-21H2,1-4H3,(H2,36,37,39)/t22-,23+,26-,28+,29-,30+,31+,32+,34-,35-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350726
PNG
(US10208081, Example 34)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)c4ccc(OC(F)(F)F)cc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H47F3N2O5S/c1-5-20-16-24-26-11-10-25(30(26,3)15-13-27(24)31(4)14-12-21(38)17-28(20)31)19(2)18-36-29(39)37-43(40,41)23-8-6-22(7-9-23)42-32(33,34)35/h6-9,19-21,24-28,38H,5,10-18H2,1-4H3,(H2,36,37,39)/t19-,20+,21-,24+,25-,26+,27+,28+,30-,31-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350731
PNG
(US10208081, Example 39 | US10208081, Example 78)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C31H55N3O5S/c1-5-22-26-19-21(35)11-14-31(26,4)25-12-15-30(3)23(9-10-24(30)27(25)28(22)36)20(2)13-16-32-29(37)33-40(38,39)34-17-7-6-8-18-34/h20-28,35-36H,5-19H2,1-4H3,(H2,32,33,37)/t20-,21-,22-,23-,24+,25+,26+,27+,28-,30-,31-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350752
PNG
(US10208081, Example 61)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)C[C@@]45CCC(CC4=O)C5(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H60N2O6S/c1-7-24-28-19-23(39)11-14-35(28,6)27-12-15-34(5)25(8-9-26(34)30(27)31(24)41)21(2)13-17-37-32(42)38-45(43,44)20-36-16-10-22(18-29(36)40)33(36,3)4/h21-28,30-31,39,41H,7-20H2,1-6H3,(H2,37,38,42)/t21-,22?,23-,24-,25-,26+,27+,28+,30+,31-,34-,35-,36+/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350759
PNG
(US10208081, Example 68)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CC5CC5C4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C31H53N3O5S/c1-5-22-26-15-21(35)8-11-31(26,4)25-9-12-30(3)23(6-7-24(30)27(25)28(22)36)18(2)10-13-32-29(37)33-40(38,39)34-16-19-14-20(19)17-34/h18-28,35-36H,5-17H2,1-4H3,(H2,32,33,37)/t18-,19?,20?,21-,22-,23-,24+,25+,26+,27+,28-,30-,31-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350761
PNG
(US10208081, Example 70)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)C(C)(C)C(=O)OC)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C37H58N2O7S/c1-8-26-30-21-24(40)15-18-37(30,6)29-16-19-36(5)27(13-14-28(36)31(29)32(26)41)22(2)17-20-38-34(43)39-47(44,45)25-11-9-23(10-12-25)35(3,4)33(42)46-7/h9-12,22,24,26-32,40-41H,8,13-21H2,1-7H3,(H2,38,39,43)/t22-,24-,26-,27-,28+,29+,30+,31+,32-,36-,37-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350775
PNG
(US10208081, Example 84)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CCN(CC4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C34H62N4O5S/c1-8-24-28-21-23(39)11-14-34(28,7)27-12-15-33(6)25(9-10-26(33)29(27)30(24)40)22(2)13-16-35-31(41)36-44(42,43)38-19-17-37(18-20-38)32(3,4)5/h22-30,39-40H,8-21H2,1-7H3,(H2,35,36,41)/t22-,23-,24-,25-,26+,27+,28+,29+,30-,33-,34-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350795
PNG
(US10208081, Example 104)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)C(F)(F)F)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C27H45F3N2O5S/c1-5-17-21-14-16(33)8-11-26(21,4)20-9-12-25(3)18(6-7-19(25)22(20)23(17)34)15(2)10-13-31-24(35)32-38(36,37)27(28,29)30/h15-23,33-34H,5-14H2,1-4H3,(H2,31,32,35)/t15-,16-,17-,18-,19+,20+,21+,22+,23-,25-,26-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350802
PNG
(US10208081, Example 111)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(s4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C34H56N2O5S2/c1-8-22-26-19-21(37)13-16-34(26,7)25-14-17-33(6)23(9-10-24(33)29(25)30(22)38)20(2)15-18-35-31(39)36-43(40,41)28-12-11-27(42-28)32(3,4)5/h11-12,20-26,29-30,37-38H,8-10,13-19H2,1-7H3,(H2,35,36,39)/t20-,21-,22-,23-,24+,25+,26+,29+,30-,33-,34-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350816
PNG
(US10208081, Example 125)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)NC)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C27H49N3O5S/c1-6-18-22-15-17(31)9-12-27(22,4)21-10-13-26(3)19(7-8-20(26)23(21)24(18)32)16(2)11-14-29-25(33)30-36(34,35)28-5/h16-24,28,31-32H,6-15H2,1-5H3,(H2,29,30,33)/t16-,17-,18-,19-,20+,21+,22+,23+,24-,26-,27-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350823
PNG
(US10208081, Example 133)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNS(=O)(=O)c4cccc(c4)N4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H58N2O4S/c1-5-28-32-23-26(39)14-17-36(32,4)31-15-18-35(3)29(12-13-30(35)33(31)34(28)40)24(2)16-19-37-43(41,42)27-11-9-10-25(22-27)38-20-7-6-8-21-38/h9-11,22,24,26,28-34,37,39-40H,5-8,12-21,23H2,1-4H3/t24-,26-,28-,29-,30+,31+,32+,33+,34-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>1.00E+4n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350695
PNG
(US10208081, Example 1)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc5ccccc5c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H52N2O5S/c1-5-27-31-21-25(39)14-17-36(31,4)30-15-18-35(3)28(12-13-29(35)32(30)33(27)40)22(2)16-19-37-34(41)38-44(42,43)26-11-10-23-8-6-7-9-24(23)20-26/h6-11,20,22,25,27-33,39-40H,5,12-19,21H2,1-4H3,(H2,37,38,41)/t22-,25-,27-,28-,29+,30+,31+,32+,33-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350696
PNG
(US10208081, Example 2)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(OC(F)(F)F)cc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H49F3N2O6S/c1-5-23-27-18-20(39)12-15-32(27,4)26-13-16-31(3)24(10-11-25(31)28(26)29(23)40)19(2)14-17-37-30(41)38-45(42,43)22-8-6-21(7-9-22)44-33(34,35)36/h6-9,19-20,23-29,39-40H,5,10-18H2,1-4H3,(H2,37,38,41)/t19-,20-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350698
PNG
(US10208081, Example 4)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccccc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H50N2O5S/c1-5-23-27-19-21(35)13-16-32(27,4)26-14-17-31(3)24(11-12-25(31)28(26)29(23)36)20(2)15-18-33-30(37)34-40(38,39)22-9-7-6-8-10-22/h6-10,20-21,23-29,35-36H,5,11-19H2,1-4H3,(H2,33,34,37)/t20-,21-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350705
PNG
(US10208081, Example 13)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cccc(C)c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H52N2O5S/c1-6-24-28-19-22(36)12-15-33(28,5)27-13-16-32(4)25(10-11-26(32)29(27)30(24)37)21(3)14-17-34-31(38)35-41(39,40)23-9-7-8-20(2)18-23/h7-9,18,21-22,24-30,36-37H,6,10-17,19H2,1-5H3,(H2,34,35,38)/t21-,22-,24-,25-,26+,27+,28+,29+,30-,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350729
PNG
(US10208081, Example 37)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CCOCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C30H53N3O6S/c1-5-21-25-18-20(34)8-11-30(25,4)24-9-12-29(3)22(6-7-23(29)26(24)27(21)35)19(2)10-13-31-28(36)32-40(37,38)33-14-16-39-17-15-33/h19-27,34-35H,5-18H2,1-4H3,(H2,31,32,36)/t19-,20-,21-,22-,23+,24+,25+,26+,27-,29-,30-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350744
PNG
(US10208081, Example 53)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cccc(c4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H58N2O5S/c1-8-26-30-21-24(39)14-17-36(30,7)29-15-18-35(6)27(12-13-28(35)31(29)32(26)40)22(2)16-19-37-33(41)38-44(42,43)25-11-9-10-23(20-25)34(3,4)5/h9-11,20,22,24,26-32,39-40H,8,12-19,21H2,1-7H3,(H2,37,38,41)/t22-,24-,26-,27-,28+,29+,30+,31+,32-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350746
PNG
(US10208081, Example 55)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc5CCCc5c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C35H54N2O5S/c1-5-26-30-20-24(38)13-16-35(30,4)29-14-17-34(3)27(11-12-28(34)31(29)32(26)39)21(2)15-18-36-33(40)37-43(41,42)25-10-9-22-7-6-8-23(22)19-25/h9-10,19,21,24,26-32,38-39H,5-8,11-18,20H2,1-4H3,(H2,36,37,40)/t21-,24-,26-,27-,28+,29+,30+,31+,32-,34-,35-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350749
PNG
(US10208081, Example 58)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc5OCCOc5c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C34H52N2O7S/c1-5-23-27-18-21(37)10-13-34(27,4)26-11-14-33(3)24(7-8-25(33)30(26)31(23)38)20(2)12-15-35-32(39)36-44(40,41)22-6-9-28-29(19-22)43-17-16-42-28/h6,9,19-21,23-27,30-31,37-38H,5,7-8,10-18H2,1-4H3,(H2,35,36,39)/t20-,21-,23-,24-,25+,26+,27+,30+,31-,33-,34-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350753
PNG
(US10208081, Example 62)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc5N(CCc5c4)C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H55N3O6S/c1-6-26-30-20-24(41)11-15-36(30,5)29-12-16-35(4)27(8-9-28(35)32(29)33(26)42)21(2)13-17-37-34(43)38-46(44,45)25-7-10-31-23(19-25)14-18-39(31)22(3)40/h7,10,19,21,24,26-30,32-33,41-42H,6,8-9,11-18,20H2,1-5H3,(H2,37,38,43)/t21-,24-,26-,27-,28+,29+,30+,32+,33-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350765
PNG
(US10208081, Example 74)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CCC5(COC5)CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H57N3O6S/c1-5-23-27-18-22(37)8-11-32(27,4)26-9-12-31(3)24(6-7-25(31)28(26)29(23)38)21(2)10-15-34-30(39)35-43(40,41)36-16-13-33(14-17-36)19-42-20-33/h21-29,37-38H,5-20H2,1-4H3,(H2,34,35,39)/t21-,22-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350767
PNG
(US10208081, Example 76)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)C4CC5CCC4C5)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H56N2O5S/c1-5-23-27-18-22(36)10-13-33(27,4)26-11-14-32(3)24(8-9-25(32)29(26)30(23)37)19(2)12-15-34-31(38)35-41(39,40)28-17-20-6-7-21(28)16-20/h19-30,36-37H,5-18H2,1-4H3,(H2,34,35,38)/t19-,20?,21?,22-,23-,24-,25+,26+,27+,28?,29+,30-,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350789
PNG
(US10208081, Example 98)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4C(C)CCC4C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H57N3O5S/c1-7-23-27-18-22(36)12-15-32(27,6)26-13-16-31(5)24(10-11-25(31)28(26)29(23)37)19(2)14-17-33-30(38)34-41(39,40)35-20(3)8-9-21(35)4/h19-29,36-37H,7-18H2,1-6H3,(H2,33,34,38)/t19-,20?,21?,22-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350794
PNG
(US10208081, Example 103)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cc(F)cc(OC)c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H51FN2O6S/c1-6-24-28-17-21(37)9-12-33(28,4)27-10-13-32(3)25(7-8-26(32)29(27)30(24)38)19(2)11-14-35-31(39)36-43(40,41)23-16-20(34)15-22(18-23)42-5/h15-16,18-19,21,24-30,37-38H,6-14,17H2,1-5H3,(H2,35,36,39)/t19-,21-,24-,25-,26+,27+,28+,29+,30-,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350801
PNG
(US10208081, Example 110)
Show SMILES C[C@H](CCNC(=O)NS(=O)(=O)c1ccc(cc1)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Show InChI InChI=1S/C34H54N2O5S/c1-21(15-18-35-31(39)36-42(40,41)25-9-7-22(8-10-25)32(2,3)4)26-11-12-27-30-28(14-17-34(26,27)6)33(5)16-13-24(37)19-23(33)20-29(30)38/h7-10,21,23-24,26-30,37-38H,11-20H2,1-6H3,(H2,35,36,39)/t21-,23+,24-,26-,27+,28+,29-,30+,33+,34-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350821
PNG
(US10208081, Example 131)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C25H45NO5S/c1-5-17-21-14-16(27)8-11-25(21,4)20-9-12-24(3)18(6-7-19(24)22(20)23(17)28)15(2)10-13-26-32(29,30)31/h15-23,26-28H,5-14H2,1-4H3,(H,29,30,31)/t15-,16-,17-,18-,19+,20+,21+,22+,23-,24-,25-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
KEGG
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350736
PNG
(US10208081, Example 45)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)C[C@H](C)NC(=O)NS(=O)(=O)C4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H58N2O4S/c1-6-23-19-26-28-13-12-27(32(28,4)17-15-29(26)33(5)16-14-24(36)20-30(23)33)21(2)18-22(3)34-31(37)35-40(38,39)25-10-8-7-9-11-25/h21-30,36H,6-20H2,1-5H3,(H2,34,35,37)/t21-,22+,23+,24-,26+,27-,28+,29+,30+,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350748
PNG
(US10208081, Example 57)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc5CCCCc5c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H56N2O5S/c1-5-27-31-21-25(39)14-17-36(31,4)30-15-18-35(3)28(12-13-29(35)32(30)33(27)40)22(2)16-19-37-34(41)38-44(42,43)26-11-10-23-8-6-7-9-24(23)20-26/h10-11,20,22,25,27-33,39-40H,5-9,12-19,21H2,1-4H3,(H2,37,38,41)/t22-,25-,27-,28-,29+,30+,31+,32+,33-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350750
PNG
(US10208081, Example 59)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)C4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C38H60N2O5S/c1-5-29-33-23-27(41)17-20-38(33,4)32-18-21-37(3)30(15-16-31(37)34(32)35(29)42)24(2)19-22-39-36(43)40-46(44,45)28-13-11-26(12-14-28)25-9-7-6-8-10-25/h11-14,24-25,27,29-35,41-42H,5-10,15-23H2,1-4H3,(H2,39,40,43)/t24-,27-,29-,30-,31+,32+,33+,34+,35-,37-,38-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350756
PNG
(US10208081, Example 65)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CCC(C)(C)CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H59N3O5S/c1-7-23-27-20-22(37)10-13-33(27,6)26-11-14-32(5)24(8-9-25(32)28(26)29(23)38)21(2)12-17-34-30(39)35-42(40,41)36-18-15-31(3,4)16-19-36/h21-29,37-38H,7-20H2,1-6H3,(H2,34,35,39)/t21-,22-,23-,24-,25+,26+,27+,28+,29-,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350776
PNG
(US10208081, Example 85)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CCN(CC4)C(=O)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C35H62N4O6S/c1-8-24-28-21-23(40)11-14-35(28,7)27-12-15-34(6)25(9-10-26(34)29(27)30(24)41)22(2)13-16-36-32(43)37-46(44,45)39-19-17-38(18-20-39)31(42)33(3,4)5/h22-30,40-41H,8-21H2,1-7H3,(H2,36,37,43)/t22-,23-,24-,25-,26+,27+,28+,29+,30-,34-,35-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350786
PNG
(US10208081, Example 95)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cccc(c4)-c4nnco4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C34H50N4O6S/c1-5-24-28-18-22(39)11-14-34(28,4)27-12-15-33(3)25(9-10-26(33)29(27)30(24)40)20(2)13-16-35-32(41)38-45(42,43)23-8-6-7-21(17-23)31-37-36-19-44-31/h6-8,17,19-20,22,24-30,39-40H,5,9-16,18H2,1-4H3,(H2,35,38,41)/t20-,22-,24-,25-,26+,27+,28+,29+,30-,33-,34-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350790
PNG
(US10208081, Example 99)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CC(C)C(C)C4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H57N3O5S/c1-7-23-27-16-22(36)10-13-32(27,6)26-11-14-31(5)24(8-9-25(31)28(26)29(23)37)19(2)12-15-33-30(38)34-41(39,40)35-17-20(3)21(4)18-35/h19-29,36-37H,7-18H2,1-6H3,(H2,33,34,38)/t19-,20?,21?,22-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350697
PNG
(US10208081, Example 127 | US10208081, Example 3 | ...)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H58N2O5S/c1-8-26-30-21-24(39)15-18-36(30,7)29-16-19-35(6)27(13-14-28(35)31(29)32(26)40)22(2)17-20-37-33(41)38-44(42,43)25-11-9-23(10-12-25)34(3,4)5/h9-12,22,24,26-32,39-40H,8,13-21H2,1-7H3,(H2,37,38,41)/t22-,24-,26-,27-,28+,29+,30+,31+,32-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350697
PNG
(US10208081, Example 127 | US10208081, Example 3 | ...)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H58N2O5S/c1-8-26-30-21-24(39)15-18-36(30,7)29-16-19-35(6)27(13-14-28(35)31(29)32(26)40)22(2)17-20-37-33(41)38-44(42,43)25-11-9-23(10-12-25)34(3,4)5/h9-12,22,24,26-32,39-40H,8,13-21H2,1-7H3,(H2,37,38,41)/t22-,24-,26-,27-,28+,29+,30+,31+,32-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350701
PNG
(US10208081, Example 7)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)C(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C29H52N2O5S/c1-7-20-24-16-19(32)10-13-29(24,6)23-11-14-28(5)21(8-9-22(28)25(23)26(20)33)18(4)12-15-30-27(34)31-37(35,36)17(2)3/h17-26,32-33H,7-16H2,1-6H3,(H2,30,31,34)/t18-,19-,20-,21-,22+,23+,24+,25+,26-,28-,29-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350717
PNG
(US10208081, Example 25)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(Cl)cc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H49ClN2O4S/c1-5-21-18-25-27-11-10-26(31(27,3)16-13-28(25)32(4)15-12-23(36)19-29(21)32)20(2)14-17-34-30(37)35-40(38,39)24-8-6-22(33)7-9-24/h6-9,20-21,23,25-29,36H,5,10-19H2,1-4H3,(H2,34,35,37)/t20-,21+,23-,25+,26-,27+,28+,29+,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350739
PNG
(US10208081, Example 48)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C30H53N3O5S/c1-5-21-25-18-20(34)10-13-30(25,4)24-11-14-29(3)22(8-9-23(29)26(24)27(21)35)19(2)12-15-31-28(36)32-39(37,38)33-16-6-7-17-33/h19-27,34-35H,5-18H2,1-4H3,(H2,31,32,36)/t19-,20-,21-,22-,23+,24+,25+,26+,27-,29-,30-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350755
PNG
(US10208081, Example 64)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cnccn4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C30H48N4O5S/c1-5-20-24-16-19(35)8-11-30(24,4)23-9-12-29(3)21(6-7-22(29)26(23)27(20)36)18(2)10-13-33-28(37)34-40(38,39)25-17-31-14-15-32-25/h14-15,17-24,26-27,35-36H,5-13,16H2,1-4H3,(H2,33,34,37)/t18-,19-,20-,21-,22+,23+,24+,26+,27-,29-,30-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350757
PNG
(US10208081, Example 66)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CCC(F)(F)CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C31H53F2N3O5S/c1-5-21-25-18-20(37)8-11-30(25,4)24-9-12-29(3)22(6-7-23(29)26(24)27(21)38)19(2)10-15-34-28(39)35-42(40,41)36-16-13-31(32,33)14-17-36/h19-27,37-38H,5-18H2,1-4H3,(H2,34,35,39)/t19-,20-,21-,22-,23+,24+,25+,26+,27-,29-,30-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350766
PNG
(US10208081, Example 75)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4C[C@H](C)O[C@H](C)C4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H57N3O6S/c1-7-23-27-16-22(36)10-13-32(27,6)26-11-14-31(5)24(8-9-25(31)28(26)29(23)37)19(2)12-15-33-30(38)34-42(39,40)35-17-20(3)41-21(4)18-35/h19-29,36-37H,7-18H2,1-6H3,(H2,33,34,38)/t19-,20-,21+,22-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350783
PNG
(US10208081, Example 92)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4c(F)c(F)c(F)c(F)c4F)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H45F5N2O5S/c1-5-17-21-14-16(40)8-11-32(21,4)20-9-12-31(3)18(6-7-19(31)22(20)28(17)41)15(2)10-13-38-30(42)39-45(43,44)29-26(36)24(34)23(33)25(35)27(29)37/h15-22,28,40-41H,5-14H2,1-4H3,(H2,38,39,42)/t15-,16-,17-,18-,19+,20+,21+,22+,28-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350785
PNG
(US10208081, Example 94)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(F)cc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H49FN2O5S/c1-5-23-27-18-21(36)12-15-32(27,4)26-13-16-31(3)24(10-11-25(31)28(26)29(23)37)19(2)14-17-34-30(38)35-41(39,40)22-8-6-20(33)7-9-22/h6-9,19,21,23-29,36-37H,5,10-18H2,1-4H3,(H2,34,35,38)/t19-,21-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350793
PNG
(US10208081, Example 102)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cc(F)cc(F)c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H48F2N2O5S/c1-5-23-27-17-21(37)8-11-32(27,4)26-9-12-31(3)24(6-7-25(31)28(26)29(23)38)18(2)10-13-35-30(39)36-42(40,41)22-15-19(33)14-20(34)16-22/h14-16,18,21,23-29,37-38H,5-13,17H2,1-4H3,(H2,35,36,39)/t18-,21-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350804
PNG
(US10208081, Example 113)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)c4ccc(cc4)C4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C37H58N2O5S/c1-5-28-32-21-26(40)17-19-37(32,4)31-18-20-36(3)29(15-16-30(36)33(31)34(28)41)23(2)22-38-35(42)39-45(43,44)27-13-11-25(12-14-27)24-9-7-6-8-10-24/h11-14,23-24,26,28-34,40-41H,5-10,15-22H2,1-4H3,(H2,38,39,42)/t23-,26-,28-,29-,30+,31+,32+,33+,34-,36-,37-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350805
PNG
(US10208081, Example 114)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)c4ccc(s4)-c4ccccc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C35H50N2O5S2/c1-5-24-28-19-23(38)15-17-35(28,4)27-16-18-34(3)25(11-12-26(34)31(27)32(24)39)21(2)20-36-33(40)37-44(41,42)30-14-13-29(43-30)22-9-7-6-8-10-22/h6-10,13-14,21,23-28,31-32,38-39H,5,11-12,15-20H2,1-4H3,(H2,36,37,40)/t21-,23-,24-,25-,26+,27+,28+,31+,32-,34-,35-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350806
PNG
(US10208081, Example 115)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)c4cccc(c4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C35H56N2O5S/c1-8-25-29-19-23(38)14-16-35(29,7)28-15-17-34(6)26(12-13-27(34)30(28)31(25)39)21(2)20-36-32(40)37-43(41,42)24-11-9-10-22(18-24)33(3,4)5/h9-11,18,21,23,25-31,38-39H,8,12-17,19-20H2,1-7H3,(H2,36,37,40)/t21-,23-,25-,26-,27+,28+,29+,30+,31-,34-,35-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350807
PNG
(US10208081, Example 116)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)c4cccc(OC(F)(F)F)c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H47F3N2O6S/c1-5-22-26-15-19(38)11-13-31(26,4)25-12-14-30(3)23(9-10-24(30)27(25)28(22)39)18(2)17-36-29(40)37-44(41,42)21-8-6-7-20(16-21)43-32(33,34)35/h6-8,16,18-19,22-28,38-39H,5,9-15,17H2,1-4H3,(H2,36,37,40)/t18-,19-,22-,23-,24+,25+,26+,27+,28-,30-,31-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350827
PNG
(US10208081, Example 138)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNS(=O)(=O)C(C)(C)C(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C29H51NO6S/c1-7-19-23-16-18(31)10-13-29(23,6)22-11-14-28(5)20(8-9-21(28)24(22)25(19)32)17(2)12-15-30-37(35,36)27(3,4)26(33)34/h17-25,30-32H,7-16H2,1-6H3,(H,33,34)/t17-,18-,19-,20-,21+,22+,23+,24+,25-,28-,29-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350699
PNG
(US10208081, Example 5)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)C4CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C29H50N2O5S/c1-5-20-24-16-18(32)10-13-29(24,4)23-11-14-28(3)21(8-9-22(28)25(23)26(20)33)17(2)12-15-30-27(34)31-37(35,36)19-6-7-19/h17-26,32-33H,5-16H2,1-4H3,(H2,30,31,34)/t17-,18-,20-,21-,22+,23+,24+,25+,26-,28-,29-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350702
PNG
(US10208081, Example 10)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(=O)NS(=O)(=O)c4ccccc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H49NO5S/c1-5-23-27-19-21(34)15-17-32(27,4)26-16-18-31(3)24(12-13-25(31)29(26)30(23)36)20(2)11-14-28(35)33-39(37,38)22-9-7-6-8-10-22/h6-10,20-21,23-27,29-30,34,36H,5,11-19H2,1-4H3,(H,33,35)/t20-,21-,23-,24-,25+,26+,27+,29+,30-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350718
PNG
(US10208081, Example 26)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCN(C)C(=O)NS(=O)(=O)c4ccc(cc4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C37H60N2O4S/c1-9-25-22-29-31-15-14-30(36(31,6)20-17-32(29)37(7)19-16-27(40)23-33(25)37)24(2)18-21-39(8)34(41)38-44(42,43)28-12-10-26(11-13-28)35(3,4)5/h10-13,24-25,27,29-33,40H,9,14-23H2,1-8H3,(H,38,41)/t24-,25+,27-,29+,30-,31+,32+,33+,36-,37-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350728
PNG
(US10208081, Example 36)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCN(C)C(=O)NS(=O)(=O)c4ccc5ccccc5c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C37H54N2O4S/c1-6-25-22-30-32-14-13-31(36(32,3)19-16-33(30)37(4)18-15-28(40)23-34(25)37)24(2)17-20-39(5)35(41)38-44(42,43)29-12-11-26-9-7-8-10-27(26)21-29/h7-12,21,24-25,28,30-34,40H,6,13-20,22-23H2,1-5H3,(H,38,41)/t24-,25+,28-,30+,31-,32+,33+,34+,36-,37-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350737
PNG
(US10208081, Example 46)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)C4(C)CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C30H52N2O5S/c1-6-20-24-17-19(33)9-12-30(24,5)23-10-13-29(4)21(7-8-22(29)25(23)26(20)34)18(2)11-16-31-27(35)32-38(36,37)28(3)14-15-28/h18-26,33-34H,6-17H2,1-5H3,(H2,31,32,35)/t18-,19-,20-,21-,22+,23+,24+,25+,26-,29-,30-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350738
PNG
(US10208081, Example 47)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CCCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H57N3O5S/c1-5-23-27-20-22(36)12-15-32(27,4)26-13-16-31(3)24(10-11-25(31)28(26)29(23)37)21(2)14-17-33-30(38)34-41(39,40)35-18-8-6-7-9-19-35/h21-29,36-37H,5-20H2,1-4H3,(H2,33,34,38)/t21-,22-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350740
PNG
(US10208081, Example 49)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccncc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C31H49N3O5S/c1-5-22-26-18-20(35)8-13-31(26,4)25-9-14-30(3)23(6-7-24(30)27(25)28(22)36)19(2)10-17-33-29(37)34-40(38,39)21-11-15-32-16-12-21/h11-12,15-16,19-20,22-28,35-36H,5-10,13-14,17-18H2,1-4H3,(H2,33,34,37)/t19-,20-,22-,23-,24+,25+,26+,27+,28-,30-,31-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350742
PNG
(US10208081, Example 51)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cccc(F)c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H49FN2O5S/c1-5-23-27-18-21(36)11-14-32(27,4)26-12-15-31(3)24(9-10-25(31)28(26)29(23)37)19(2)13-16-34-30(38)35-41(39,40)22-8-6-7-20(33)17-22/h6-8,17,19,21,23-29,36-37H,5,9-16,18H2,1-4H3,(H2,34,35,38)/t19-,21-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350747
PNG
(US10208081, Example 56)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)N(C)S(=O)(=O)c4ccccc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H52N2O5S/c1-6-24-28-20-22(36)14-17-33(28,4)27-15-18-32(3)25(12-13-26(32)29(27)30(24)37)21(2)16-19-34-31(38)35(5)41(39,40)23-10-8-7-9-11-23/h7-11,21-22,24-30,36-37H,6,12-20H2,1-5H3,(H,34,38)/t21-,22-,24-,25-,26+,27+,28+,29+,30-,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350697
PNG
(US10208081, Example 127 | US10208081, Example 3 | ...)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H58N2O5S/c1-8-26-30-21-24(39)15-18-36(30,7)29-16-19-35(6)27(13-14-28(35)31(29)32(26)40)22(2)17-20-37-33(41)38-44(42,43)25-11-9-23(10-12-25)34(3,4)5/h9-12,22,24,26-32,39-40H,8,13-21H2,1-7H3,(H2,37,38,41)/t22-,24-,26-,27-,28+,29+,30+,31+,32-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350731
PNG
(US10208081, Example 39 | US10208081, Example 78)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C31H55N3O5S/c1-5-22-26-19-21(35)11-14-31(26,4)25-12-15-30(3)23(9-10-24(30)27(25)28(22)36)20(2)13-16-32-29(37)33-40(38,39)34-17-7-6-8-18-34/h20-28,35-36H,5-19H2,1-4H3,(H2,32,33,37)/t20-,21-,22-,23-,24+,25+,26+,27+,28-,30-,31-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350771
PNG
(US10208081, Example 80)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cccc(c4)-c4nc(C)cs4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H53N3O5S2/c1-6-26-30-19-24(40)12-15-36(30,5)29-13-16-35(4)27(10-11-28(35)31(29)32(26)41)21(2)14-17-37-34(42)39-46(43,44)25-9-7-8-23(18-25)33-38-22(3)20-45-33/h7-9,18,20-21,24,26-32,40-41H,6,10-17,19H2,1-5H3,(H2,37,39,42)/t21-,24-,26-,27-,28+,29+,30+,31+,32-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350773
PNG
(US10208081, Example 82)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4C[C@@H](C)O[C@H](C)C4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H57N3O6S/c1-7-23-27-16-22(36)10-13-32(27,6)26-11-14-31(5)24(8-9-25(31)28(26)29(23)37)19(2)12-15-33-30(38)34-42(39,40)35-17-20(3)41-21(4)18-35/h19-29,36-37H,7-18H2,1-6H3,(H2,33,34,38)/t19-,20-,21-,22-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350784
PNG
(US10208081, Example 93)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(C)cc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H52N2O5S/c1-6-24-28-19-22(36)13-16-33(28,5)27-14-17-32(4)25(11-12-26(32)29(27)30(24)37)21(3)15-18-34-31(38)35-41(39,40)23-9-7-20(2)8-10-23/h7-10,21-22,24-30,36-37H,6,11-19H2,1-5H3,(H2,34,35,38)/t21-,22-,24-,25-,26+,27+,28+,29+,30-,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350803
PNG
(US10208081, Example 112)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cccc(c4)N(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C34H55N3O5S/c1-7-25-29-20-23(38)13-16-34(29,4)28-14-17-33(3)26(11-12-27(33)30(28)31(25)39)21(2)15-18-35-32(40)36-43(41,42)24-10-8-9-22(19-24)37(5)6/h8-10,19,21,23,25-31,38-39H,7,11-18,20H2,1-6H3,(H2,35,36,40)/t21-,23-,25-,26-,27+,28+,29+,30+,31-,33-,34-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350809
PNG
(US10208081, Example 118)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)c4ccc(cc4)N4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H57N3O5S/c1-5-27-31-21-25(40)15-17-36(31,4)30-16-18-35(3)28(13-14-29(35)32(30)33(27)41)23(2)22-37-34(42)38-45(43,44)26-11-9-24(10-12-26)39-19-7-6-8-20-39/h9-12,23,25,27-33,40-41H,5-8,13-22H2,1-4H3,(H2,37,38,42)/t23-,25-,27-,28-,29+,30+,31+,32+,33-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350820
PNG
(US10208081, Example 130)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CCC([C@H](C)CCNS(=O)(=O)c4ccccc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C31H49NO4S/c1-5-23-27-19-21(33)13-16-31(27,4)26-14-17-30(3)24(11-12-25(30)28(26)29(23)34)20(2)15-18-32-37(35,36)22-9-7-6-8-10-22/h6-10,20-21,23-29,32-34H,5,11-19H2,1-4H3/t20-,21-,23-,24?,25+,26+,27+,28+,29-,30-,31-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350826
PNG
(US10208081, Example 137)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCCNS(=O)(=O)c4ccccc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H53NO4S/c1-5-25-29-21-23(35)16-18-33(29,4)28-17-19-32(3)26(14-15-27(32)30(28)31(25)36)22(2)11-9-10-20-34-39(37,38)24-12-7-6-8-13-24/h6-8,12-13,22-23,25-31,34-36H,5,9-11,14-21H2,1-4H3/t22-,23-,25-,26-,27+,28+,29+,30+,31-,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350706
PNG
(US10208081, Example 14)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)C(F)(F)F)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H49F3N2O5S/c1-5-23-27-18-21(39)12-15-32(27,4)26-13-16-31(3)24(10-11-25(31)28(26)29(23)40)19(2)14-17-37-30(41)38-44(42,43)22-8-6-20(7-9-22)33(34,35)36/h6-9,19,21,23-29,39-40H,5,10-18H2,1-4H3,(H2,37,38,41)/t19-,21-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350707
PNG
(US10208081, Example 15)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(OC)cc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H52N2O6S/c1-6-24-28-19-21(36)13-16-33(28,4)27-14-17-32(3)25(11-12-26(32)29(27)30(24)37)20(2)15-18-34-31(38)35-42(39,40)23-9-7-22(41-5)8-10-23/h7-10,20-21,24-30,36-37H,6,11-19H2,1-5H3,(H2,34,35,38)/t20-,21-,24-,25-,26+,27+,28+,29+,30-,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350710
PNG
(US10208081, Example 18)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCNC(=O)NS(=O)(=O)c4ccc(OC(F)(F)F)cc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C34H51F3N2O6S/c1-5-24-28-19-21(40)14-16-33(28,4)27-15-17-32(3)25(12-13-26(32)29(27)30(24)41)20(2)7-6-18-38-31(42)39-46(43,44)23-10-8-22(9-11-23)45-34(35,36)37/h8-11,20-21,24-30,40-41H,5-7,12-19H2,1-4H3,(H2,38,39,42)/t20-,21-,24-,25-,26+,27+,28+,29+,30-,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350715
PNG
(US10208081, Example 23)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc5OCOc5c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H50N2O6S/c1-5-21-16-24-26-8-7-25(32(26,3)14-11-27(24)33(4)13-10-22(36)17-28(21)33)20(2)12-15-34-31(37)35-42(38,39)23-6-9-29-30(18-23)41-19-40-29/h6,9,18,20-22,24-28,36H,5,7-8,10-17,19H2,1-4H3,(H2,34,35,37)/t20-,21+,22-,24+,25-,26+,27+,28+,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350720
PNG
(US10208081, Example 28)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C30H54N2O4S/c1-8-20-17-22-24-10-9-23(19(2)13-16-31-27(34)32-37(35,36)28(3,4)5)29(24,6)15-12-25(22)30(7)14-11-21(33)18-26(20)30/h19-26,33H,8-18H2,1-7H3,(H2,31,32,34)/t19-,20+,21-,22+,23-,24+,25+,26+,29-,30-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350727
PNG
(US10208081, Example 35)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCN(C)C(=O)NS(=O)(=O)C4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H58N2O4S/c1-6-23-20-26-28-13-12-27(32(28,3)18-15-29(26)33(4)17-14-24(36)21-30(23)33)22(2)16-19-35(5)31(37)34-40(38,39)25-10-8-7-9-11-25/h22-30,36H,6-21H2,1-5H3,(H,34,37)/t22-,23+,24-,26+,27-,28+,29+,30+,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350733
PNG
(US10208081, Example 41)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)C4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C31H54N2O4S/c1-5-21-17-24-26-12-11-25(20(2)19-32-29(35)33-38(36,37)23-9-7-6-8-10-23)30(26,3)16-14-27(24)31(4)15-13-22(34)18-28(21)31/h20-28,34H,5-19H2,1-4H3,(H2,32,33,35)/t20-,21+,22-,24+,25-,26+,27+,28+,30-,31-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350734
PNG
(US10208081, Example 42)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)N4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C30H53N3O4S/c1-5-21-17-23-25-10-9-24(20(2)19-31-28(35)32-38(36,37)33-15-7-6-8-16-33)29(25,3)14-12-26(23)30(4)13-11-22(34)18-27(21)30/h20-27,34H,5-19H2,1-4H3,(H2,31,32,35)/t20-,21+,22-,23+,24-,25+,26+,27+,29-,30-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350772
PNG
(US10208081, Example 81)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CC(F)(F)C(F)(F)C4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C30H49F4N3O5S/c1-5-19-23-14-18(38)8-11-28(23,4)22-9-12-27(3)20(6-7-21(27)24(22)25(19)39)17(2)10-13-35-26(40)36-43(41,42)37-15-29(31,32)30(33,34)16-37/h17-25,38-39H,5-16H2,1-4H3,(H2,35,36,40)/t17-,18-,19-,20-,21+,22+,23+,24+,25-,27-,28-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350774
PNG
(US10208081, Example 83)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CCS(=O)(=O)CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C30H53N3O7S2/c1-5-21-25-18-20(34)8-11-30(25,4)24-9-12-29(3)22(6-7-23(29)26(24)27(21)35)19(2)10-13-31-28(36)32-42(39,40)33-14-16-41(37,38)17-15-33/h19-27,34-35H,5-18H2,1-4H3,(H2,31,32,36)/t19-,20-,21-,22-,23+,24+,25+,26+,27-,29-,30-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350777
PNG
(US10208081, Example 86)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CCC5(CC5)CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H57N3O5S/c1-5-23-27-20-22(37)8-11-32(27,4)26-9-12-31(3)24(6-7-25(31)28(26)29(23)38)21(2)10-17-34-30(39)35-42(40,41)36-18-15-33(13-14-33)16-19-36/h21-29,37-38H,5-20H2,1-4H3,(H2,34,35,39)/t21-,22-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350779
PNG
(US10208081, Example 88)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)C4CCC(CC4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H64N2O5S/c1-8-26-30-21-24(39)15-18-36(30,7)29-16-19-35(6)27(13-14-28(35)31(29)32(26)40)22(2)17-20-37-33(41)38-44(42,43)25-11-9-23(10-12-25)34(3,4)5/h22-32,39-40H,8-21H2,1-7H3,(H2,37,38,41)/t22-,23?,24-,25?,26-,27-,28+,29+,30+,31+,32-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350780
PNG
(US10208081, Example 89)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)C4CCC(F)(F)CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H54F2N2O5S/c1-5-22-26-18-20(37)8-13-31(26,4)25-11-14-30(3)23(6-7-24(30)27(25)28(22)38)19(2)12-17-35-29(39)36-42(40,41)21-9-15-32(33,34)16-10-21/h19-28,37-38H,5-18H2,1-4H3,(H2,35,36,39)/t19-,20-,22-,23-,24+,25+,26+,27+,28-,30-,31-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350782
PNG
(US10208081, Example 128 | US10208081, Example 91)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C28H51N3O5S/c1-7-19-23-16-18(32)10-13-28(23,4)22-11-14-27(3)20(8-9-21(27)24(22)25(19)33)17(2)12-15-29-26(34)30-37(35,36)31(5)6/h17-25,32-33H,7-16H2,1-6H3,(H2,29,30,34)/t17-,18-,19-,20-,21+,22+,23+,24+,25-,27-,28-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350792
PNG
(US10208081, Example 101)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)C4CCC(C)(C)CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C34H60N2O5S/c1-7-24-28-20-22(37)10-17-34(28,6)27-13-18-33(5)25(8-9-26(33)29(27)30(24)38)21(2)14-19-35-31(39)36-42(40,41)23-11-15-32(3,4)16-12-23/h21-30,37-38H,7-20H2,1-6H3,(H2,35,36,39)/t21-,22-,24-,25-,26+,27+,28+,29+,30-,33-,34-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350796
PNG
(US10208081, Example 105)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)Nc4ccc(cc4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H59N3O5S/c1-8-26-30-21-25(40)15-18-36(30,7)29-16-19-35(6)27(13-14-28(35)31(29)32(26)41)22(2)17-20-37-33(42)39-45(43,44)38-24-11-9-23(10-12-24)34(3,4)5/h9-12,22,25-32,38,40-41H,8,13-21H2,1-7H3,(H2,37,39,42)/t22-,25-,26-,27-,28+,29+,30+,31+,32-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350800
PNG
(US10208081, Example 109)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cnn(CC)c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C31H52N4O5S/c1-6-22-26-16-20(36)10-13-31(26,5)25-11-14-30(4)23(8-9-24(30)27(25)28(22)37)19(3)12-15-32-29(38)34-41(39,40)21-17-33-35(7-2)18-21/h17-20,22-28,36-37H,6-16H2,1-5H3,(H2,32,34,38)/t19-,20-,22-,23-,24+,25+,26+,27+,28-,30-,31-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350808
PNG
(US10208081, Example 117)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)c4ccc5OCOc5c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H48N2O7S/c1-5-21-25-14-19(35)10-12-32(25,4)24-11-13-31(3)22(7-8-23(31)28(24)29(21)36)18(2)16-33-30(37)34-42(38,39)20-6-9-26-27(15-20)41-17-40-26/h6,9,15,18-19,21-25,28-29,35-36H,5,7-8,10-14,16-17H2,1-4H3,(H2,33,34,37)/t18-,19-,21-,22-,23+,24+,25+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350812
PNG
(US10208081, Example 121)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)c4cccc(c4)N4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H57N3O5S/c1-5-27-31-21-25(40)14-16-36(31,4)30-15-17-35(3)28(12-13-29(35)32(30)33(27)41)23(2)22-37-34(42)38-45(43,44)26-11-9-10-24(20-26)39-18-7-6-8-19-39/h9-11,20,23,25,27-33,40-41H,5-8,12-19,21-22H2,1-4H3,(H2,37,38,42)/t23-,25-,27-,28-,29+,30+,31+,32+,33-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350813
PNG
(US10208081, Example 122)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)C(C)(C)CO)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C30H54N2O6S/c1-7-20-24-16-19(34)10-13-30(24,6)23-11-14-29(5)21(8-9-22(29)25(23)26(20)35)18(2)12-15-31-27(36)32-39(37,38)28(3,4)17-33/h18-26,33-35H,7-17H2,1-6H3,(H2,31,32,36)/t18-,19-,20-,21-,22+,23+,24+,25+,26-,29-,30-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350814
PNG
(US10208081, Example 123)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)C(=O)OC)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C34H52N2O7S/c1-6-24-28-19-22(37)13-16-34(28,4)27-14-17-33(3)25(11-12-26(33)29(27)30(24)38)20(2)15-18-35-32(40)36-44(41,42)23-9-7-21(8-10-23)31(39)43-5/h7-10,20,22,24-30,37-38H,6,11-19H2,1-5H3,(H2,35,36,40)/t20-,22-,24-,25-,26+,27+,28+,29+,30-,33-,34-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350817
PNG
(US10208081, Example 126)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)NC)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@H](C[C@@H]12)OC(=O)C(F)(F)F
Show InChI InChI=1S/C29H48F3N3O6S/c1-6-18-22-15-17(41-25(37)29(30,31)32)9-12-28(22,4)21-10-13-27(3)19(7-8-20(27)23(21)24(18)36)16(2)11-14-34-26(38)35-42(39,40)33-5/h16-24,33,36H,6-15H2,1-5H3,(H2,34,35,38)/t16-,17-,18-,19-,20+,21+,22+,23+,24-,27-,28-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350782
PNG
(US10208081, Example 128 | US10208081, Example 91)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C28H51N3O5S/c1-7-19-23-16-18(32)10-13-28(23,4)22-11-14-27(3)20(8-9-21(27)24(22)25(19)33)17(2)12-15-29-26(34)30-37(35,36)31(5)6/h17-25,32-33H,7-16H2,1-6H3,(H2,29,30,34)/t17-,18-,19-,20-,21+,22+,23+,24+,25-,27-,28-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350822
PNG
(US10208081, Example 132)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNS(=O)(=O)CC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C27H47NO6S/c1-5-18-22-14-17(29)8-11-27(22,4)21-9-12-26(3)19(6-7-20(26)24(21)25(18)32)16(2)10-13-28-35(33,34)15-23(30)31/h16-22,24-25,28-29,32H,5-15H2,1-4H3,(H,30,31)/t16-,17-,18-,19-,20+,21+,22+,24+,25-,26-,27-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350824
PNG
(US10208081, Example 135)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCNS(=O)(=O)O[Na])[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C26H47NO5S.Na/c1-5-18-22-15-17(28)10-12-26(22,4)21-11-13-25(3)19(8-9-20(25)23(21)24(18)29)16(2)7-6-14-27-33(30,31)32;/h16-24,27-29H,5-15H2,1-4H3,(H,30,31,32);/q;+1/p-1/t16-,17-,18-,19-,20+,21+,22+,23+,24-,25-,26-;/m1./s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350825
PNG
(US10208081, Example 136)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCCNS(=O)(=O)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C31H57NO4S/c1-8-22-26-19-21(33)14-16-31(26,7)25-15-17-30(6)23(12-13-24(30)27(25)28(22)34)20(2)11-9-10-18-32-37(35,36)29(3,4)5/h20-28,32-34H,8-19H2,1-7H3/t20-,21-,22-,23-,24+,25+,26+,27+,28-,30-,31-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM21674
PNG
((4R)-4-[(1S,2S,5R,7S,9R,10R,11S,14R,15R)-5,9-dihyd...)
Show SMILES C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Show InChI InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
Purchase

CHEBI
DrugBank
KEGG
MMDB
PC cid
PC sid
PDB
UniChem

Patents


Similars

DrugBank
US Patent
n/an/an/an/a>1.00E+4n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350711
PNG
(US10208081, Example 19)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCNC(=O)NS(=O)(=O)c4ccc5ccccc5c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C37H54N2O5S/c1-5-28-32-22-26(40)16-18-37(32,4)31-17-19-36(3)29(14-15-30(36)33(31)34(28)41)23(2)9-8-20-38-35(42)39-45(43,44)27-13-12-24-10-6-7-11-25(24)21-27/h6-7,10-13,21,23,26,28-34,40-41H,5,8-9,14-20,22H2,1-4H3,(H2,38,39,42)/t23-,26-,28-,29-,30+,31+,32+,33+,34-,36-,37-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350713
PNG
(US10208081, Example 21)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cccs4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C30H48N2O4S2/c1-5-20-17-22-24-9-8-23(19(2)12-15-31-28(34)32-38(35,36)27-7-6-16-37-27)29(24,3)14-11-25(22)30(4)13-10-21(33)18-26(20)30/h6-7,16,19-26,33H,5,8-15,17-18H2,1-4H3,(H2,31,32,34)/t19-,20+,21-,22+,23-,24+,25+,26+,29-,30-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350721
PNG
(US10208081, Example 29)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(C)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C26H46N2O4S/c1-6-17-13-19-21-8-7-20(16(2)15-27-24(30)28-33(5,31)32)25(21,3)12-10-22(19)26(4)11-9-18(29)14-23(17)26/h16-23,29H,6-15H2,1-5H3,(H2,27,28,30)/t16-,17+,18-,19+,20-,21+,22+,23+,25-,26-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350725
PNG
(US10208081, Example 33)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)c4ccc(cc4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C35H56N2O4S/c1-8-23-19-27-29-14-13-28(34(29,6)18-16-30(27)35(7)17-15-25(38)20-31(23)35)22(2)21-36-32(39)37-42(40,41)26-11-9-24(10-12-26)33(3,4)5/h9-12,22-23,25,27-31,38H,8,13-21H2,1-7H3,(H2,36,37,39)/t22-,23+,25-,27+,28-,29+,30+,31+,34-,35-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350730
PNG
(US10208081, Example 38)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cccc5ccccc45)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H52N2O4S/c1-5-24-21-28-30-14-13-29(35(30,3)19-16-31(28)36(4)18-15-26(39)22-32(24)36)23(2)17-20-37-34(40)38-43(41,42)33-12-8-10-25-9-6-7-11-27(25)33/h6-12,23-24,26,28-32,39H,5,13-22H2,1-4H3,(H2,37,38,40)/t23-,24+,26-,28+,29-,30+,31+,32+,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350741
PNG
(US10208081, Example 50)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cccc(OC(F)(F)F)c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H49F3N2O6S/c1-5-23-27-17-20(39)11-14-32(27,4)26-12-15-31(3)24(9-10-25(31)28(26)29(23)40)19(2)13-16-37-30(41)38-45(42,43)22-8-6-7-21(18-22)44-33(34,35)36/h6-8,18-20,23-29,39-40H,5,9-17H2,1-4H3,(H2,37,38,41)/t19-,20-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350743
PNG
(US10208081, Example 52)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N(C(C)C)C(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H59N3O5S/c1-9-23-27-18-22(36)12-15-32(27,8)26-13-16-31(7)24(10-11-25(31)28(26)29(23)37)21(6)14-17-33-30(38)34-41(39,40)35(19(2)3)20(4)5/h19-29,36-37H,9-18H2,1-8H3,(H2,33,34,38)/t21-,22-,23-,24-,25+,26+,27+,28+,29-,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350754
PNG
(US10208081, Example 63)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)Cc4ccccc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H52N2O5S/c1-5-24-28-19-23(36)13-16-33(28,4)27-14-17-32(3)25(11-12-26(32)29(27)30(24)37)21(2)15-18-34-31(38)35-41(39,40)20-22-9-7-6-8-10-22/h6-10,21,23-30,36-37H,5,11-20H2,1-4H3,(H2,34,35,38)/t21-,23-,24-,25-,26+,27+,28+,29+,30-,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350762
PNG
(US10208081, Example 71)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)-c4csc(C)n4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H53N3O5S2/c1-6-26-30-19-24(40)13-16-36(30,5)29-14-17-35(4)27(11-12-28(35)32(29)33(26)41)21(2)15-18-37-34(42)39-46(43,44)25-9-7-23(8-10-25)31-20-45-22(3)38-31/h7-10,20-21,24,26-30,32-33,40-41H,6,11-19H2,1-5H3,(H2,37,39,42)/t21-,24-,26-,27-,28+,29+,30+,32+,33-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350764
PNG
(US10208081, Example 73)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4OC)-c4ccno4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H53N3O7S/c1-6-24-28-20-23(40)11-15-36(28,4)27-12-16-35(3)25(8-9-26(35)32(27)33(24)41)21(2)13-17-37-34(42)39-47(43,44)31-10-7-22(19-30(31)45-5)29-14-18-38-46-29/h7,10,14,18-19,21,23-28,32-33,40-41H,6,8-9,11-13,15-17,20H2,1-5H3,(H2,37,39,42)/t21-,23-,24-,25-,26+,27+,28+,32+,33-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350778
PNG
(US10208081, Example 87)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NC(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C30H54N2O3/c1-8-20-24-17-19(33)11-14-30(24,7)23-12-15-29(6)21(9-10-22(29)25(23)26(20)34)18(2)13-16-31-27(35)32-28(3,4)5/h18-26,33-34H,8-17H2,1-7H3,(H2,31,32,35)/t18-,19-,20-,21-,22+,23+,24+,25+,26-,29-,30-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350781
PNG
(US10208081, Example 90)
Show SMILES CCCCS(=O)(=O)NC(=O)NCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)[C@H](CC)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Show InChI InChI=1S/C30H54N2O5S/c1-6-8-17-38(36,37)32-28(35)31-16-13-19(3)22-9-10-23-26-24(12-15-29(22,23)4)30(5)14-11-20(33)18-25(30)21(7-2)27(26)34/h19-27,33-34H,6-18H2,1-5H3,(H2,31,32,35)/t19-,20-,21-,22-,23+,24+,25+,26+,27-,29-,30-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350787
PNG
(US10208081, Example 96)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4[C@@H](C)CCC[C@H]4C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H59N3O5S/c1-7-24-28-19-23(37)13-16-33(28,6)27-14-17-32(5)25(11-12-26(32)29(27)30(24)38)20(2)15-18-34-31(39)35-42(40,41)36-21(3)9-8-10-22(36)4/h20-30,37-38H,7-19H2,1-6H3,(H2,34,35,39)/t20-,21-,22+,23-,24-,25-,26+,27+,28+,29+,30-,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350791
PNG
(US10208081, Example 100)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4nccs4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C29H47N3O5S2/c1-5-19-23-16-18(33)8-11-29(23,4)22-9-12-28(3)20(6-7-21(28)24(22)25(19)34)17(2)10-13-30-26(35)32-39(36,37)27-31-14-15-38-27/h14-15,17-25,33-34H,5-13,16H2,1-4H3,(H2,30,32,35)/t17-,18-,19-,20-,21+,22+,23+,24+,25-,28-,29-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350798
PNG
(US10208081, Example 107)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4cccc5ncccc45)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C35H51N3O5S/c1-5-23-28-20-22(39)13-16-35(28,4)27-14-17-34(3)25(11-12-26(34)31(27)32(23)40)21(2)15-19-37-33(41)38-44(42,43)30-10-6-9-29-24(30)8-7-18-36-29/h6-10,18,21-23,25-28,31-32,39-40H,5,11-17,19-20H2,1-4H3,(H2,37,38,41)/t21-,22-,23-,25-,26+,27+,28+,31+,32-,34-,35-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350799
PNG
(US10208081, Example 108)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(s4)-c4ccccc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H52N2O5S2/c1-5-25-29-21-24(39)15-18-36(29,4)28-16-19-35(3)26(11-12-27(35)32(28)33(25)40)22(2)17-20-37-34(41)38-45(42,43)31-14-13-30(44-31)23-9-7-6-8-10-23/h6-10,13-14,22,24-29,32-33,39-40H,5,11-12,15-21H2,1-4H3,(H2,37,38,41)/t22-,24-,25-,26-,27+,28+,29+,32+,33-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350828
PNG
(US10208081, Example 139)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNS(=O)(=O)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C29H53NO4S/c1-8-20-24-17-19(31)11-14-29(24,7)23-12-15-28(6)21(9-10-22(28)25(23)26(20)32)18(2)13-16-30-35(33,34)27(3,4)5/h18-26,30-32H,8-17H2,1-7H3/t18-,19-,20-,21-,22+,23+,24+,25+,26-,28-,29-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350700
PNG
(US10208081, Example 6)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(C)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C27H48N2O5S/c1-6-18-22-15-17(30)9-12-27(22,4)21-10-13-26(3)19(7-8-20(26)23(21)24(18)31)16(2)11-14-28-25(32)29-35(5,33)34/h16-24,30-31H,6-15H2,1-5H3,(H2,28,29,32)/t16-,17-,18-,19-,20+,21+,22+,23+,24-,26-,27-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350703
PNG
(US10208081, Example 11)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(=O)NS(=O)(=O)C(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C29H51NO5S/c1-7-20-24-16-19(31)12-14-29(24,6)23-13-15-28(5)21(9-10-22(28)26(23)27(20)33)18(4)8-11-25(32)30-36(34,35)17(2)3/h17-24,26-27,31,33H,7-16H2,1-6H3,(H,30,32)/t18-,19-,20-,21-,22+,23+,24+,26+,27-,28-,29-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350704
PNG
(US10208081, Example 12)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCNC(=O)NS(=O)(=O)c4ccc(cc4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C37H60N2O5S/c1-8-27-31-22-25(40)17-19-37(31,7)30-18-20-36(6)28(15-16-29(36)32(30)33(27)41)23(2)10-9-21-38-34(42)39-45(43,44)26-13-11-24(12-14-26)35(3,4)5/h11-14,23,25,27-33,40-41H,8-10,15-22H2,1-7H3,(H2,38,39,42)/t23-,25-,27-,28-,29+,30+,31+,32+,33-,36-,37-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350708
PNG
(US10208081, Example 16)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(C)c(F)c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H51FN2O5S/c1-6-23-27-17-21(37)11-14-33(27,5)26-12-15-32(4)24(9-10-25(32)29(26)30(23)38)19(2)13-16-35-31(39)36-42(40,41)22-8-7-20(3)28(34)18-22/h7-8,18-19,21,23-27,29-30,37-38H,6,9-17H2,1-5H3,(H2,35,36,39)/t19-,21-,23-,24-,25+,26+,27+,29+,30-,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350712
PNG
(US10208081, Example 20)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCNC(=O)NS(=O)(=O)C4CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C30H52N2O5S/c1-5-21-25-17-19(33)12-14-30(25,4)24-13-15-29(3)22(10-11-23(29)26(24)27(21)34)18(2)7-6-16-31-28(35)32-38(36,37)20-8-9-20/h18-27,33-34H,5-17H2,1-4H3,(H2,31,32,35)/t18-,19-,21-,22-,23+,24+,25+,26+,27-,29-,30-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350714
PNG
(US10208081, Example 22)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)C4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H56N2O4S/c1-5-22-19-25-27-12-11-26(31(27,3)17-14-28(25)32(4)16-13-23(35)20-29(22)32)21(2)15-18-33-30(36)34-39(37,38)24-9-7-6-8-10-24/h21-29,35H,5-20H2,1-4H3,(H2,33,34,36)/t21-,22+,23-,25+,26-,27+,28+,29+,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350732
PNG
(US10208081, Example 40)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccccc4Cl)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C32H49ClN2O4S/c1-5-21-18-23-25-11-10-24(31(25,3)16-13-26(23)32(4)15-12-22(36)19-27(21)32)20(2)14-17-34-30(37)35-40(38,39)29-9-7-6-8-28(29)33/h6-9,20-27,36H,5,10-19H2,1-4H3,(H2,34,35,37)/t20-,21+,22-,23+,24-,25+,26+,27+,31-,32-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350735
PNG
(US10208081, Example 43)
Show SMILES CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CNC(=O)NS(=O)(=O)N4CCOCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C29H51N3O5S/c1-5-20-16-22-24-7-6-23(19(2)18-30-27(34)31-38(35,36)32-12-14-37-15-13-32)28(24,3)11-9-25(22)29(4)10-8-21(33)17-26(20)29/h19-26,33H,5-18H2,1-4H3,(H2,30,31,34)/t19-,20+,21-,22+,23-,24+,25+,26+,28-,29-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350745
PNG
(US10208081, Example 54)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)-c4ccccc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C38H54N2O5S/c1-5-29-33-23-27(41)17-20-38(33,4)32-18-21-37(3)30(15-16-31(37)34(32)35(29)42)24(2)19-22-39-36(43)40-46(44,45)28-13-11-26(12-14-28)25-9-7-6-8-10-25/h6-14,24,27,29-35,41-42H,5,15-23H2,1-4H3,(H2,39,40,43)/t24-,27-,29-,30-,31+,32+,33+,34+,35-,37-,38-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350751
PNG
(US10208081, Example 60)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)C[C@]45CCC(CC4=O)C5(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H60N2O6S/c1-7-24-28-19-23(39)11-14-35(28,6)27-12-15-34(5)25(8-9-26(34)30(27)31(24)41)21(2)13-17-37-32(42)38-45(43,44)20-36-16-10-22(18-29(36)40)33(36,3)4/h21-28,30-31,39,41H,7-20H2,1-6H3,(H2,37,38,42)/t21-,22?,23-,24-,25-,26+,27+,28+,30+,31-,34-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350758
PNG
(US10208081, Example 67)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4CCC(CC4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C35H63N3O5S/c1-8-25-29-21-24(39)11-16-35(29,7)28-12-17-34(6)26(9-10-27(34)30(28)31(25)40)22(2)13-18-36-32(41)37-44(42,43)38-19-14-23(15-20-38)33(3,4)5/h22-31,39-40H,8-21H2,1-7H3,(H2,36,37,41)/t22-,24-,25-,26-,27+,28+,29+,30+,31-,34-,35-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350760
PNG
(US10208081, Example 69)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)C(C)(C)CO)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H58N2O6S/c1-7-26-30-20-24(40)14-17-36(30,6)29-15-18-35(5)27(12-13-28(35)31(29)32(26)41)22(2)16-19-37-33(42)38-45(43,44)25-10-8-23(9-11-25)34(3,4)21-39/h8-11,22,24,26-32,39-41H,7,12-21H2,1-6H3,(H2,37,38,42)/t22-,24-,26-,27-,28+,29+,30+,31+,32-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350763
PNG
(US10208081, Example 72)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4C)-c4ccno4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H53N3O6S/c1-6-25-29-20-24(40)11-15-36(29,5)28-12-16-35(4)26(8-9-27(35)32(28)33(25)41)21(2)13-17-37-34(42)39-46(43,44)31-10-7-23(19-22(31)3)30-14-18-38-45-30/h7,10,14,18-19,21,24-29,32-33,40-41H,6,8-9,11-13,15-17,20H2,1-5H3,(H2,37,39,42)/t21-,24-,25-,26-,27+,28+,29+,32+,33-,35-,36-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350770
PNG
(US10208081, Example 79)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4C)-c4cnc(C)o4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C37H55N3O6S/c1-7-26-30-19-25(41)12-15-37(30,6)29-13-16-36(5)27(9-10-28(36)33(29)34(26)42)21(2)14-17-38-35(43)40-47(44,45)32-11-8-24(18-22(32)3)31-20-39-23(4)46-31/h8,11,18,20-21,25-30,33-34,41-42H,7,9-10,12-17,19H2,1-6H3,(H2,38,40,43)/t21-,25-,26-,27-,28+,29+,30+,33+,34-,36-,37-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350788
PNG
(US10208081, Example 97)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)N4C[C@@H](C)C[C@@H](C)C4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H59N3O5S/c1-7-24-28-17-23(37)10-13-33(28,6)27-11-14-32(5)25(8-9-26(32)29(27)30(24)38)22(4)12-15-34-31(39)35-42(40,41)36-18-20(2)16-21(3)19-36/h20-30,37-38H,7-19H2,1-6H3,(H2,34,35,39)/t20-,21+,22-,23-,24-,25-,26+,27+,28+,29+,30-,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350797
PNG
(US10208081, Example 106)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)C4(CC4)C(F)(F)F)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C36H53F3N2O5S/c1-5-25-29-20-23(42)12-15-34(29,4)28-13-16-33(3)26(10-11-27(33)30(28)31(25)43)21(2)14-19-40-32(44)41-47(45,46)24-8-6-22(7-9-24)35(17-18-35)36(37,38)39/h6-9,21,23,25-31,42-43H,5,10-20H2,1-4H3,(H2,40,41,44)/t21-,23-,25-,26-,27+,28+,29+,30+,31-,33-,34-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350810
PNG
(US10208081, Example 119)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)N(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C34H55N3O5S/c1-7-25-29-20-23(38)14-17-34(29,4)28-15-18-33(3)26(12-13-27(33)30(28)31(25)39)21(2)16-19-35-32(40)36-43(41,42)24-10-8-22(9-11-24)37(5)6/h8-11,21,23,25-31,38-39H,7,12-20H2,1-6H3,(H2,35,36,40)/t21-,23-,25-,26-,27+,28+,29+,30+,31-,33-,34-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a<100n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350811
PNG
(US10208081, Example 120)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)C(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C33H50N2O7S/c1-5-23-27-18-21(36)12-15-33(27,4)26-13-16-32(3)24(10-11-25(32)28(26)29(23)37)19(2)14-17-34-31(40)35-43(41,42)22-8-6-20(7-9-22)30(38)39/h6-9,19,21,23-29,36-37H,5,10-18H2,1-4H3,(H,38,39)(H2,34,35,40)/t19-,21-,23-,24-,25+,26+,27+,28+,29-,32-,33-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350815
PNG
(US10208081, Example 124)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(N)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C26H47N3O5S/c1-5-17-21-14-16(30)8-11-26(21,4)20-9-12-25(3)18(6-7-19(25)22(20)23(17)31)15(2)10-13-28-24(32)29-35(27,33)34/h15-23,30-31H,5-14H2,1-4H3,(H2,27,33,34)(H2,28,29,32)/t15-,16-,17-,18-,19+,20+,21+,22+,23-,25-,26-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor


(Homo sapiens (Human))
BDBM350829
PNG
(US10208081, Example 141)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNS(=O)(=O)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1S/C28H49NO6S/c1-5-19-23-16-18(30)8-12-28(23,4)22-9-13-27(3)20(6-7-21(27)25(22)26(19)33)17(2)10-14-29-36(34,35)15-11-24(31)32/h17-23,25-26,29-30,33H,5-16H2,1-4H3,(H,31,32)/t17-,18-,19-,20-,21+,22+,23+,25+,26-,27-,28-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.50E+3n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k...


US Patent US10208081 (2019)

More data for this
Ligand-Target Pair
* indicates data uncertainty>20%